Articles On Amplia Therapeutics (ASX:ATX)

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Oncology radiology leader Telix Pharmaceuticals is taking on the US, Tim Boreham reports. By Tim Boreham ASX Code: ((TLX)) Share price: $11.26 Shares on issue: 318,808,268 Market cap: $3.58 billion Chief executive officer: Dr Christian Behr...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

HIGHLIGHTS Amplia’s highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer FOLFIRINOX is the most widely used treatment for pancreatic cancer patients...

Tissue Repairs and Radiopharm surge after US FDA meetings Avecho granted application approval by US Patent Office Amplia demonstrated efficacy of its pancreatic drug   Tissue Repair to progress to Phase 3 Wound healing specialist Tissue R...

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

Amplia Therapeutics (ASX:ATX) has received grant funding to undertake a research collaboration with Australia’s national science agency CSIRO to develop novel topical formulations of the company’s FAK inhibitors.

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

The ASX opened lower this morning, while majority of the sectors dragged. Finance and communications fell 0.5 per cent, while healthcare also took a hit – down 0.13 per cent. However, Amplia Therapeutics (ATX) appeared immune to the...

Amplia Therapeutics (ATX) receives grant funding to support research collaboration with Australia’s national science agency, CSIRO The company will work with CSIRO to develop formulations of its small molecule FAK inhibitors that can be...

The ASX is set to fall modestly lower on Monday on debt ceiling uncertainties Foot Locker plunged 27% after slow sales in Q1 Climate and energy set to be established as the third pillar of the Australia-US alliance   Aussie shares are se...

Amplia Therapeutics (ASX:ATX) has announced the completion of enrolment of the third cohort of patients in the ongoing Phase 1b/2a ACCENT clinical trial in frontline patients with pancreatic cancer.

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Amplia Therapeutics (ATX) recruits and doses the first patient in cohort three of its ongoing ACCENT trial for pancreatic cancer Under the third cohort, patients will receive an increased dosage of ATX’s AMP945 product, following the sa...

The ASX is expected to open flat on Wednesday following a muted session on Wall Street. Yesterday, the RBA released its April minutes for when it decided to pause further rates hikes, detailing that it was a close but necessary decision...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Amplia Therapeutics (ATX) appoints Christopher Burns as CEO and Managing Director, effective from December 5Dr Burns has more than 30 years of experience in drug discovery and development and has served in multiple executive positions for p...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

27 new biotech companies listed on the ASX the last two years Australian companies need access to US capital to grow The AusBiotech investment conference kicks off next week in WA   The Covid-19 pandemic put Australia’s biotechnology sect...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Amplia Therapeutics (ATX) releases data from two mice studies, showing potential for its AMP886 drug to reduce cancer in patients with acute myeloid leukaemia (AML)One study showed mice inoculated with MV4-11 cells who were then treated wit...

ASX 200 gains 1%  Small Caps index does the same, but then gives it all back ODE wins and NIC MD Justin Werner: Hengjaya joins world’s best nickel resources   The ASX Emerging Companies index (XEC) has given all away its early gains on Mo...

Dr John Lambert (ATX) resigns as CEO and Managing Director from Amplia Therapeutics, effective NovemberThe company says he will be available to assist with an orderly transition of the role and has commenced the search for a new CEOCommenti...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Small caps burn rest of field. Again. Up 1.8% ASX 200 dips. Again DM1 jumps 75% over two sessions   The ASX Emerging Companies (XEC) index has climbed more than 1.8% higher on Wednesday while its erstwhile brethren which measures the favo...

Telix Pharmaceuticals' prostate cancer imaging product Illucix is quickly conquering the USA, but management at the firm has (much) higher ambitions. ASX Code: ((TLX)) Market cap: $2.02bn Shares on issue: 312,916,341 Chief executive officer...

The ASX 200 is down, the XEC surged late, up 1.5%  Tech stocks rise, Cons discretionary and energy dragging US Futures flat, Chinese markets higher on Pelosi goes to Taipei day   Ahead of the close here in Sydney, US Futures connected to...

Amplia Therapeutics (ATX) doses its first patient in a clinical trial of AMP945 The trial is designed to enhance the efficacy of gemcitabine/nab-paclitaxel chemotherapy for people with advanced pancreatic cancer undergoing first-line treat...

The ASX 200 is flat as, the XEC small caps index is down 0.7%  It’s RBA day, no real surprises US Futures are lower, Chinese markets sink   Local markets are giving back what little they got from morning trade following the reserve bank o...

Amplia Therapeutics (ASX:ATX) has announced that an abstract describing its ACCENT clinical trial of AMP945 in first-line patients with advanced pancreatic cancer has been accepted for presentation at the American Association for Ca...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

The ASX 200 ends ever so slightly up, XEC finds 0.4% Gains in consumer discretionary, tech offset big losses for energy, resources, materials. South Korea, Kiwi’s lift rates ahead of tonight’s US CPI read Investors are facing crunch time...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Highlights The HREC gave a green signal to NeuroScientific for conducting an early-phase clinical trial of its lead drug candidate. The trial will evaluate the biomarkers in human blood samples that provide proof for the working mechan...

Emerging companies fall 0.7% ASX200 0.8% lower Superior Resources (ASX:SPQ) jumps on copper system find, Galileo up … heaps in May   The Emerging Companies (XEC) index is lower on Thursday, weighed down by broad losses as Credit Suisse a...

Amplia Therapeutics (ATX) releases new data showing its AMP945 treatment returns similar efficacy results to the current standard of care for idiopathic pulmonary fibrosis New data from Amplia’s preclinical studies demonstrated AMP945 show...

Alterity to launch Phase 2 clinical trial Pro Medicus signs multimillion dollar deal Amplia demonstrates efficacy for lead asset, AMP945 Alterity to launch Phase 2 clinical trial Neurodegenerative diseases specialist, Alterity Therapeutic...

ASX 200 will open lower after a fall on Wall Street overnight OPEC+ will meet to discuss higher output The ASX gets a new CEO Aussie shares are set to fall this morning after Wall Street finished lower following a volatile session overnig...

Highlights Amplia Therapeutics has received second HREC clearance for Phase 2 clinical trial of AMP945 The approval will allow the company to accelerate recruitment into the trial and focus on its execution phase The trial is designed...

ASX is set to end the week lower San Fran Fed President Mary Daly signals that a 75bp hike may be off the cards Bitcoin’s crash this week is the biggest since May 2021 ASX to fall, Bitcoin crashes Aussie shares are set to open lower agai...

Amplia Therapeutics (ATX) receives the final ethics clearance to conduct a phase two clinical trial The company gained approval from a second Human Research Ethics Committee (HREC) for the clinical trial of its Focal Adhesion Kinase (FAK)...

Amplia Therapeutics’ (ATX) pre-investigational new drug (IND) interaction with the US Food and Drug Administration is given the green light The company sought the FDA’s feedback on the design of its planned clinical study of its AMP945 tre...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...